The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 16 April 2026•Updated 17 April 2026•

1 min read

GRAIL Partners With Epic to Expand Access to Galleri Cancer Detection Test

Key Facts

1GRAIL announced a partnership with Epic to integrate its Galleri cancer detection test into Electronic Health Record (EHR) systems.

about 2 months ago

Version History

Version 1about 2 months ago

What changed: The story was updated to include Tempus AI's expansion of its GenoPredicta platform and its use of AI and Whole Genome Sequencing in oncology diagnostics.

GRAIL has announced a strategic partnership with Epic to integrate its Galleri multi-cancer early detection test into Electronic Health Record (EHR) systems across 450 U.S. health systems. Adding to this industry momentum, Tempus AI has expanded its strategic partnership by scaling the GenoPredicta rollout and deepening its collaborations within the oncology sector. Tempus AI is increasingly leveraging artificial intelligence and Whole Genome Sequencing (WGS) to advance the frontiers of cancer diagnostics and genomic research. These combined efforts aim to reduce administrative friction for physicians while significantly increasing the adoption rates of advanced screening tools. This shift underscores a broader trend in healthcare where AI-driven diagnostics and seamless data integration are becoming central to improving patient outcomes through early intervention.